Alterity Therapeutics (ATHE) completes 1-for-50 share consolidation and trading reset
Rhea-AI Filing Summary
Alterity Therapeutics Limited is implementing a 1 for 50 consolidation of its share capital following shareholder approval at an Extraordinary General Meeting on 29 May 2026. This reduces each holder’s number of shares, with fractional entitlements rounded up to at least one security and the share price adjusted accordingly.
From 3 June to the close of trading on 11 June 2026, Alterity securities trade on the ASX on a post-consolidation, deferred settlement basis under temporary code “ATHDA”, with a record date of 4 June 2026. Listed options “ATHO” and “ATHOA” temporarily trade as “ATHDB” and “ATHDC”. Normal T+2 trading under the “ATH” code resumes on 12 June 2026.
Positive
- None.
Negative
- None.
Insights
Alterity is executing a 1-for-50 reverse split with temporary ASX codes.
Alterity Therapeutics is consolidating its share capital on a 1 for 50 basis, a mechanical change that reduces the number of shares while increasing the per-share price proportionally. Fractional holdings are rounded up to ensure each shareholder retains at least one security.
During the transition, trading occurs on a deferred settlement basis under temporary ASX codes for both shares and listed options. Normal T+2 trading under the standard “ATH” code resumes on 12 June 2026, so the operational impact is limited to the defined trading window.
Key Figures
Key Terms
deferred settlement basis financial
T+2 settlement basis financial
Phase 3 pivotal trial medical
randomized, double-blind, placebo-controlled Phase 2 clinical trial medical
Multiple System Atrophy (MSA) medical
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-163
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2026
Alterity Therapeutics Limited
(Name of Registrant)
Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)
ALTERITY THERAPEUTICS LIMITED
(a development stage enterprise)
The following exhibits are submitted:
|
99.1 |
Share Consolidation Effective, Trading Under ATHDA |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Alterity Therapeutics Limited |
||
|
By: |
/s/ Julian Babarczy |
|
|
Julian Babarczy |
||
|
Chairman |
||
Date: June 4, 2026
Exhibit 99.1
Share Consolidation and ASX Code
‒ Alterity shares to trade under the temporary ticker of “ATHDA” until 12 June ‒
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 4 June 2026: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, advises that, further to shareholder approval received at the Extraordinary General Meeting on 29 May, 2026, the consolidation of the Company’s share capital on a 1 for 50 basis is now being actioned.
From 3 June 2026 until the close of trading on 11 June 2026, trading in the Company’s securities takes place on a post-consolidation and deferred settlement basis under a temporary ASX code “ATHDA”, with a record date of 4 June 2026.
Additionally, the Company’s “ATHO” and “ATHOA” listed options will trade under temporary codes “ATHDB” and “ATHDC” respectively on a deferred settlement basis.
Normal trading (on a T+2 settlement basis) commences 12 June under ASX code “ATH”.
Shareholders are reminded that the number of shares they hold has been reduced in accordance with the 1 for 50 consolidation ratio, with any fractional entitlements rounded up to the nearest whole number (to a minimum of 1 security). The Company’s share price has adjusted accordingly.
For more information, please refer to the Company’s ASX Announcements on Consolidation and Notice of General Meeting released to the ASX.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at www.alteritytx.com.
Authorization & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
Contacts:
Investors
Elyse Shapiro
ir@alteritytx.com
Remy Bernarda
Investor Relations Advisory Solutions
ir@alteritytx.com
+1 (415) 203-6386
Media
Casey McDonald
Tiberend Strategic Advisors, Inc.
cmcdonald@tiberend.com
+1 (646) 577-8520